Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety surveillance of Empaveli in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis
jRCT2031260416Recruiting
- Sponsor
- Sobi
- Start
- Sep 2026
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Primary immune complex membranoproliferative glomerulonephritis (MPGN), sponsored by Sobi. Primary endpoints: Meningococcal infection after Empaveli discontinuation and Non-meningococcal infections after Empaveli discontinuation. Started Sep 2026; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on jRCT2031260416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260416.